Global Finance News
09 Oct 2026, 14:37
Alignment Healthcare Stock Plunges 16.4% After William Blair Downgrade
Alignment Healthcare shares fell 16.4% to $7.29 after William Blair downgraded the stock to Market Perform from Outperform, with the move tied to concerns over the company’s 2027 Medicare Advantage Star Ratings.
The key issue is Alignment’s California H3815 HMO contract, which received a 3.5-star rating for 2027, down from 4.0 stars for 2026 (Benzinga). The contract is particularly important because it represents more than 75% of the company’s total health plan membership.
Medicare Advantage contracts generally need a rating of at least 4 stars to qualify for quality bonus payments, meaning the downgrade could pressure future economics for Alignment’s largest plan (Benzinga).
The company performed better across much of the rest of its portfolio, with six of seven eligible contracts receiving ratings of 4 stars or higher. However, investors appear to be focusing on the financial impact of the California downgrade rather than the broader portfolio strength.
Alignment has challenged the methodology behind the rating and said it intends to pursue administrative remedies and litigation over measures it believes should be reviewed (Benzinga).
The sharp stock decline suggests the market is pricing in a potentially meaningful hit to future bonus revenue and profitability if the H3815 rating remains below the 4-star threshold.
Alignment Healthcare shares fell 16.4% to $7.29 after William Blair downgraded the stock to Market Perform from Outperform, with the move tied to concerns over the company’s 2027 Medicare Advantage Star Ratings.
The key issue is Alignment’s California H3815 HMO contract, which received a 3.5-star rating for 2027, down from 4.0 stars for 2026 (Benzinga). The contract is particularly important because it represents more than 75% of the company’s total health plan membership.
Medicare Advantage contracts generally need a rating of at least 4 stars to qualify for quality bonus payments, meaning the downgrade could pressure future economics for Alignment’s largest plan (Benzinga).
The company performed better across much of the rest of its portfolio, with six of seven eligible contracts receiving ratings of 4 stars or higher. However, investors appear to be focusing on the financial impact of the California downgrade rather than the broader portfolio strength.
Alignment has challenged the methodology behind the rating and said it intends to pursue administrative remedies and litigation over measures it believes should be reviewed (Benzinga).
The sharp stock decline suggests the market is pricing in a potentially meaningful hit to future bonus revenue and profitability if the H3815 rating remains below the 4-star threshold.
